Does cosentyx affect vaccine immunity?

Does Cosentyx affect vaccine immunity?

Cosentyx (secukinumab) is a biologic drug that targets interleukin-17A to treat autoimmune conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by suppressing parts of the immune system.

How does Cosentyx change the immune response to vaccines?

Cosentyx inhibits IL-17A, which can weaken the body’s ability to form strong antibody responses after vaccination. Studies show patients taking Cosentyx produce lower antibody levels to vaccines like influenza and pneumococcal vaccines compared to those who do not take the drug. However, many patients still reach protective antibody levels.

What vaccines are recommended before starting Cosentyx?

Patients should receive all age-appropriate vaccines, especially live vaccines, before treatment begins. Live vaccines are contraindicated during Cosentyx therapy because the drug’s immune suppression could allow the weakened virus to cause disease. Non-live vaccines can generally be given while on Cosentyx, but effectiveness may be reduced.

What happens if you get vaccinated while on Cosentyx?

Non-live vaccines can sicher be received during treatment. Effectiveness may drop, but the risk of adverse events is similar between patients on Cosentyx and those who not. Studies on tetanus, influenza, and pneumococcal vaccines show that patients on Cosentyx continue to receive the benefits of vaccination even with reduced antibody levels.

What side effects are patients asking about?

Patients report common side effects like upper respiratory infections, diarrhea, and headache. Vaccine-related concerns often include whether Cosentyx can increase the risk of infection from live vaccines or reduce vaccine effectiveness. Data from clinical trials and post-marketing reports suggest no increased risk for non-live vaccines.

When does patent expire for Cosentyx?

Cosentyx has multiple patents covering formulation, method of use, and composition. One key patent expires in 2027, but secondary patents may extend exclusivity beyond that date. DrugPatentWatch.com